Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene clues may explain why light therapy helps some transplant patients

NCT ID NCT07316829

Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at gene activity in blood cells from 30 kidney or lung transplant patients who have chronic rejection. Researchers want to find out why some patients improve with a treatment called extracorporeal photoapheresis (ECP) while others do not. The goal is to better understand the body's response, not to test a new cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adult kidney and lung transplant recipients diagnosed with chronic antibody-mediated rejection (AMCR) or chronic lung allograft dysfunction (CLAD), respectively.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Kidney transplant recipients with biopsy-proven AMCR * Lung transplant recipients with CLAD, defined as a persistent decline in FEV1 ≥ 20% compared with post-transplant baseline in the absence of other causes * Patients receiving standard immunosuppressive therapy and eligible for Extracorporeal Photoapheresis (ECP) * Ability to provide informed consent Exclusion Criteria: * Active infection or uncontrolled comorbidities that contraindicate ECP * Pregnancy or breastfeeding * Participation in another interventional trial that could interfere with outcomes * Inability to comply with study procedures Additional Notes: * Both prevalent and incident cases may be included (ambispective design). * Patients will be followed longitudinally for clinical outcomes, donor-specific antibodies, and gene expression profiling at baseline, 6 months, and 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antibodies, donor-specific are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute transplant rejection Bronchiolitis Obliterans bronchiolitis obliterans syndrome Chronic Disease chronic transplant rejection transplant rejection transplant-related bronchiolitis obliterans

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antibodies, donor-specific Antibody-mediated rejection Bronchiolitis obliterans Chronic disease Graft rejection HLA antibodies Immune tolerance Kidney transplantation Lung transplantation

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    Pavia, Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.